However, early clinical trial results focusing on IDH inhibitors alone have shown modest efficacy in treating chondrosarcoma, suggesting that combination therapy may be a more effective approach for future treatment strategies [19,20]. The gene discussed is IDH1; the disease is chondrosarcoma.